Patents-Review.com
ClassID:

116417 ⎘

C12Y301/06013 - CPC Classification

Classification description:

Hydrolases acting on ester bonds (3.1); Sulfuric ester hydrolases (3.1.6) Iduronate-2-sulfatase (3.1.6.13)

Recent Application in this class:
#1
20260152730
2026-06-04

GENE THERAPY CONSTRUCTS FOR METABOLIC DISORDERS

 #2
20260078178
2026-03-19

METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS

 #3
20250387477
2025-12-25

ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF

 #4
20250381296
2025-12-18

Nucleic Acid Molecule, Vector, Recombinant Cells, and Drug for Treating Central Nervous System Disease

 #5
20250375506
2025-12-11

CNS DELIVERY OF THERAPEUTIC AGENTS

 #6
20250367284
2025-12-04

ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF

 #7
20250352670
2025-11-20

DELIVERING GENES TO THE BRAIN ENDOTHELIUM TO TREAT LYSOSOMAL STORAGE DISORDER-DERIVED NEUROPATHOLOGY

 #8
20250345402
2025-11-13

GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II

 #9
20250257339
2025-08-14

AFFINITY CHROMATOGRAPHY USING AN ELUTION BUFFER COMPRISING GLYCINE AND ARGININE

 #10
20250257338
2025-08-14

GLYCOPROTEIN HAVING REDUCED NUMBER OF MANNOSE-6-PHOSPHATES

 #11
20250161417
2025-05-22

METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A

 #12
20250121040
2025-04-17

METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE

 #13
20250059292
2025-02-20

Fusion Protein of Anti-Transferrin Receptor Antibody and Physiologically Active Protein for Safe Gene Therapy

 #14
20250051740
2025-02-13

TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS

 #15
20250019408
2025-01-16

CD40L ANTAGONIST AND USES THEREOF

 #16
20240409650
2024-12-12

METHODS AND COMPOSITIONS FOR INCREASING N-ACETYLGLUCOSAMINIDASE ACTIVITY IN THE CNS

 #17
20240401010
2024-12-05

COMPOSITIONS COMPRISING IDURONATE-2-SULFATASE

 #18
20240366789
2024-11-07

AAV-IDS VECTORS FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS II

 #19
20240350653
2024-10-24

TARGETED DELIVERY OF THERAPEUTIC ENZYMES

 #20
20240327507
2024-10-03

METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATE ACTIVITY IN THE CNS

 #21
20240216481
2024-07-04

COMPOSITION FOR TREATING OF FACIAL DYSMORPHISM IN MUCOPOLYSACCHARIDOSIS

 #22
20240197921
2024-06-20

SIGNAL PEPTIDES

 #23
20240148866
2024-05-09

ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF

 #24
20240117328
2024-04-11

TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS)

 #25
20240066149
2024-02-29

Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity

 #26
20240058426
2024-02-22

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)

 #27
20240043817
2024-02-08

COMPOSITIONS COMPRISING IDURONATE-2-SULFATASE

 #28
20240016903
2024-01-18

GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II

 #29
20230330195
2023-10-19

METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGIC DISEASE

 #30
20230310712
2023-10-05

IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF

 #31
20230277634
2023-09-07

APPLICATION OF MICROBIAL GLYCOSIDASE AS AN ANTI-VIRAL THERAPEUTIC, PROGNOSTIC, AND DIAGNOSTIC

 #32
20230165942
2023-06-01

CNS DELIVERY OF THERAPEUTIC AGENTS

 #33
20230149519
2023-05-18

Variant sulfatase enzymes with enhanced properties

 #34
20230092681
2023-03-23

METHODS FOR THE TREATMENT OF HUNTER SYNDROME

 #35
20230088992
2023-03-23

TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS

 #36
20230067653
2023-03-02

ENGINEERED TARGET SPECIFIC NUCLEASES

 #37
20230038295
2023-02-09

ADENO-ASSOCIATED VIRUS PACKAGING SYSTEMS

 #38
20230026836
2023-01-26

Methods and compositions for CNS delivery of iduronate-2-sulfatase

 #39
20220204952
2022-06-30

PRODUCTION OF CATALYTICALLY ACTIVE TYPE I SULFATASE

 #40
20220184186
2022-06-16

FORMULATIONS OF PROTEIN MOLECULES COMPRISING IDURONATE 2-SULFATASE

 #41
20220133863
2022-05-05

TREATMENT OF SANFILIPPO SYNDROME TYPE B

 #42
20220133862
2022-05-05

Methods and compositions for CNS delivery of heparan N-sulfatase

 #43
20220125949
2022-04-28

GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II

 #44
20220096659
2022-03-31

METHOD FOR IMPROVING NEUROLOGICAL FUNCTION IN MPSI AND MPSII AND OTHER NEUROLOGICAL DISORDERS

 #45
20220025065
2022-01-27

LYSOSOMAL STORAGE DISORDER BIOMARKERS AND METHODS OF USE THEREOF

 #46
20220002688
2022-01-06

PURIFICATION OF IDURONATE-2-SULFATASE IMMUNOGLOBULIN FUSION PROTEIN

 #47
20210361778
2021-11-25

ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR IDS GENE TRANSFER AND METHODS OF USE THEREOF

 #48
20210332383
2021-10-28

Adeno associated virus vectors for the treatment of hunter disease

 #49
20210324094
2021-10-21

Fusion protein comprising IDS and use thereof

 #50
20210317426
2021-10-14

Compositions comprising iduronate-2-sulfatase

 #51
20210253681
2021-08-19

Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS

 #52
20210228692
2021-07-29

INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES

 #53
20210213109
2021-07-15

METHOD AND COMPOSITION FOR TREATING HUNTER SYNDROME THROUGH CEREBRAL LATERAL VENTRICLE ADMINISTRATION

 #54
20210198653
2021-07-01

DELIVERING ENZYME USING AN INJECTABLE HYDROGEL DEPOT

 #55
20210198640
2021-07-01

Fusion proteins comprising enzyme replacement therapy enzymes

 #56
20210187082
2021-06-24

Lyophilized preparation

 #57
20210180069
2021-06-17

STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES

 #58
20210061918
2021-03-04

Aqueous pharmaceutical composition

 #59
20200405825
2020-12-31

Methods and compositions for CNS delivery of arylsulfatase A

 #60
20200376093
2020-12-03

Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

 #61
20200277584
2020-09-03

FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES

 #62
20200270590
2020-08-27

P97-IDS fusion proteins

 #63
20200268857
2020-08-27

Methods and compositions for treating hunter syndrome

 #64
20200246486
2020-08-06

Method for the treatment of mucopolysaccharidosis type I

 #65
20200246439
2020-08-06

Gene therapy for treating Mucopolysaccharidosis type II

 #66
20200231989
2020-07-23

Methods and compositions for the treatment of lysosomal storage diseases

 #67
20200230253
2020-07-23

CONJUGATE OF IDURONATE-2-SULFATASE

 #68
20200157172
2020-05-21

NOVEL THERAPEUTIC ENZYME FUSION PROTEIN AND USE THEREOF

 #69
20200149019
2020-05-14

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells

 #70
20200113981
2020-04-16

CNS delivery of therapeutic agents

 #71
20200093899
2020-03-26

HUNTER SYNDROME THERAPEUTIC AGENT AND TREATMENT METHOD

 #72
20200071743
2020-03-05

ENZYMATIC ASSAYS FOR QUANTIFYING THERAPY IN SUBJECTS WITH MUCOPOLYSACCHARIDOSIS TYPE I OR II

 #73
20200071721
2020-03-05

GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS, TYPE II

 #74
20200046810
2020-02-13

Methods and compositions for CNS delivery of iduronate-2-sulfatase

 #75
20190359958
2019-11-28

METHODS AND COMPOSITIONS FOR TREATMENT OF HUNTER SYNDROME

 #76
20190269799
2019-09-05

METHOD FOR IMPROVING NEUROLOGICAL FUNCTION IN MPSI AND MPSII AND OTHER NEUROLOGICAL DISORDERS

 #77
20190249155
2019-08-15

Fusion proteins comprising enzyme replacement therapy enzymes

 #78
20190241877
2019-08-08

Engineered target specific nucleases

 #79
20190225700
2019-07-25

Method for producing antibody fusion protein

 #80
20190185551
2019-06-20

Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS

 #81
20190183984
2019-06-20

Methods and compositions for CNS delivery of heparan n-sulfatase

 #82
20190153450
2019-05-23

Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides

 #83
20190127726
2019-05-02

Delivering enzyme using an injectable hydrogel depot

 #84
20190083582
2019-03-21

INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES

 #85
20190070311
2019-03-07

Gene therapy for treating mucopolysaccharidosis type II

 #86
20190040368
2019-02-07

PRODUCTION OF CATALYTICALLY ACTIVE TYPE I SULFATASE

 #87
20180303914
2018-10-25

Hunter syndrome therapeutic agent and treatment method

 #88
20180264089
2018-09-20

MODIFIED IDURONATE 2-SULFATASE AND PRODUCTION THEREOF

 #89
20180258408
2018-09-13

MODIFIED LYSOSOMAL PROTEIN AND PRODUCTION THEREOF

 #90
20180251535
2018-09-06

METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS

 #91
20180185495
2018-07-05

THERAPEUTIC COMPOSITIONS OF ALPHA-L-IDURONIDASE, IDURONATE-2-SULFATASE, AND ALPHA-GALACTOSIDASE A AND METHODS OF USE THEREOF

 #92
20180169272
2018-06-21

Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

 #93
20180168134
2018-06-21

TRANSGENIC MOUSE EXPRESSING INACTIVATED HUMAN IDURONATE-2-SULPHATASE AND METHOD FOR IMPROVING A HUNTER SYNDROME TREATING AGENT USING SAME

 #94
20180127733
2018-05-10

IDURONATE-2-SULFATASE AND USE THEREOF

 #95
20180112199
2018-04-26

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

 #96
20180085438
2018-03-29

Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety

 #97
20180071371
2018-03-15

Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

 #98
20180071212
2018-03-15

Methods and compositions for CNS delivery of arylsulfatase A

 #99
20180036386
2018-02-08

METHODS AND COMPOSITIONS FOR INTRATHECALLY ADMINISTERED TREATMENT OF MUCUPOLYSACCHARIDOSIS TYPE IIIA

 #100
20180030424
2018-02-01

IDURONATE-2-SULFATASE AND USE THEREOF

 #101
20180010108
2018-01-11

CELLS FOR PRODUCING RECOMBINANT IDURONATE-2-SULFATASE

 #102
20170219566
2017-08-03

Substrate clearance assays for lysosomal enzymes

 #103
20170204386
2017-07-20

P97-IDS fusion proteins

 #104
20170202931
2017-07-20

METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGIC DISEASE

 #105
20170073652
2017-03-16

Methods and compositions for treatment of Hunter syndrome

 #106
20170042978
2017-02-16

CNS delivery of therapeutic agents

 #107
20160369001
2016-12-22

Anti-human transferrin receptor antibody that passes through blood-brain barrier

 #108
20160367703
2016-12-22

DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES

 #109
20160367691
2016-12-22

TARGETED ENZYME COMPOUNDS AND USES THEREOF

 #110
20160326504
2016-11-10

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

 #111
20160208006
2016-07-21

Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

 #112
20160158324
2016-06-09

METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE

 #113
20160145589
2016-05-26

COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF

 #114
20160136293
2016-05-19

Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides

 #115
20160122731
2016-05-05

Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses

 #116
20160060656
2016-03-03

Method of treating mucopolysaccharidosis type I or II

 #117
20160053238
2016-02-25

Cells for producing recombinant iduronate-2-sulfatase

 #118
20150328289
2015-11-19

Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

 #119
20150320843
2015-11-12

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

 #120
20150313972
2015-11-05

Methods and compositions for treatment of hunter syndrome

 #121
20150313971
2015-11-05

METHODS AND COMPOSITIONS FOR INTRATHECALLY ADMINISTERED TREATMENT OF MUCUPOLYSACCHARIDOSIS TYPE IIIA

 #122
20150313970
2015-11-05

Intraventricular enzyme delivery for lysosomal storage diseases

 #123
20150290341
2015-10-15

TARGETED IDURONATE-2-SULFATASE COMPOUNDS

 #124
20150086526
2015-03-26

Subcutaneous administration of iduronate-2-sulfatase

 #125
20150050664
2015-02-19

Assay for measuring enzymatic modification of a substrate by a glycoprotein having enzymatic activity

 #126
20150037311
2015-02-05

TARGETED LYSOSOMAL ENZYME COMPOUNDS

 #127
20150004160
2015-01-01

Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS

 #128
20140335163
2014-11-13

TARGETED IDURONATE-2-SULFATASE COMPOUNDS

 #129
20140242059
2014-08-28

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

 #130
20140171491
2014-06-19

Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

 #131
20140004096
2014-01-02

Purification of iduronate-2-sulfatase

 #132
20130330802
2013-12-12

Method for production of recombinant human iduronate 2-sulfatase

 #133
20130302308
2013-11-14

Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses

 #134
20130295077
2013-11-07

Treatment of Sanfilippo syndrome type B by intrathecal administration of alpha-n-acetylglucosaminidase

 #135
20130028881
2013-01-31

DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES

 #136
20120288489
2012-11-15

Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

 #137
20120009171
2012-01-12

Methods and compositions for CNS delivery of arylsulfatase A

 #138
20120003202
2012-01-05

CNS delivery of therapeutic agents

 #139
20110318327
2011-12-29

TREATMENT OF SANFILIPPO SYNDROME TYPE B

 #140
20110318324
2011-12-29

METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE

 #141
20110318323
2011-12-29

Methods and compositions for CNS delivery of iduronate-2-sulfatase

 #142
20110110935
2011-05-12

Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS

 #143
20090130079
2009-05-21

Intraventricular enzyme delivery for lysosomal storage diseases